具核梭杆菌与结直肠癌发生发展的研究进展

国际肿瘤学杂志››2022,Vol. 49››Issue (2): 121-124.doi:10.3760/cma.j.cn371439-20210202-00020

具核梭杆菌与结直肠癌发生发展的研究进展

贺小康¹, 涂贤², 姚菲², 吴清明^1,²()

¹武汉科技大学附属天佑医院消化内科,武汉 430064
²武汉科技大学医学院,武汉430065

收稿日期:2021-02-02修回日期:2021-06-03出版日期:2022-02-08发布日期:2022-03-11
通讯作者:吴清明 E-mail:wuhe9224@sina.com
基金资助:
国家自然科学基金(81573239);国家级大学生创新创业训练计划(201722146029)

Research progress ofFusobacterium nucleatumand occurrence and development of colorectal cancer

He Xiaokang¹, Tu Xian², Yao Fei², Wu Qingming^1,²()

¹Department of Gastroenterology, Tianyou Hospital, Wuhan University of Science and Technology, Wuhan 430064, China
²Medical College, Wuhan University of Science and Technology, Wuhan 430065, China

Received:2021-02-02Revised:2021-06-03Online:2022-02-08Published:2022-03-11
Contact:Wu Qingming E-mail:wuhe9224@sina.com
Supported by:
National Natural Science Foundation of China(81573239);National Undergraduate Training Program for Innovation and Entrepreneurship(201722146029)

摘要/Abstract

摘要：

结直肠癌(CRC)是消化道常见恶性肿瘤,严重威胁人类的健康。近年来研究发现,具核梭杆菌(Fn)与CRC的发生呈正相关。在CRC癌变的发生过程中,Fn可通过诱导促炎性细胞因子的表达从而引发慢性炎症反应、抑制免疫细胞的功能、诱导化疗耐药、促进肿瘤基因和微小RNA表达、调控糖酵解等途径发挥重要作用。

贺小康, 涂贤, 姚菲, 吴清明. 具核梭杆菌与结直肠癌发生发展的研究进展[J]. 国际肿瘤学杂志, 2022, 49(2): 121-124.

He Xiaokang, Tu Xian, Yao Fei, Wu Qingming. Research progress ofFusobacterium nucleatumand occurrence and development of colorectal cancer[J]. Journal of International Oncology, 2022, 49(2): 121-124.

参考文献32

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30. DOI: 10.3322/caac.21590. doi:10.3322/caac.21590
[2]	Hashemi Goradel N, Heidarzadeh S, Jahangiri S, et al. Fusobacte-rium nucleatum and colorectal cancer: a mechanistic overview[J]. J Cell Physiol, 2019, 234(3): 2337-2344. DOI: 10.1002/jcp.27250. doi:10.1002/jcp.27250pmid:30191984
[3]	Mima K, Nishihara R, Qian ZR, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis[J]. Gut, 2016, 65(12): 1973-1980. DOI: 10.1136/gutjnl-2015-310101. doi:10.1136/gutjnl-2015-310101
[4]	Tunsjø HS, Gundersen G, Rangnes F, et al. Detection of Fusobacterium nucleatum in stool and colonic tissues from Norwegian colorectal cancer patients[J]. Eur J Clin Microbiol Infect Dis, 2019, 38(7): 1367-1376. DOI: 10.1007/s10096-019-03562-7. doi:10.1007/s10096-019-03562-7
[5]	Signat B, Roques C, Poulet P, et al. Fusobacterium nucleatum in periodontal health and disease[J]. Curr Issues Mol Biol, 2011, 13(2): 25-36.
[6]	Allen-Vercoe E, Strauss J, Chadee K. Fusobacterium nucleatum: an emerging gut pathogen?[J]. Gut Microbes, 2011, 2(5): 294-298. DOI: 10.4161/gmic.2.5.18603. doi:10.4161/gmic.2.5.18603pmid:22067936
[7]	Castellarin M, Warren RL, Freeman JD, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma[J]. Genome Res, 2012, 22(2): 299-306. DOI: 10.1101/gr.126516.111. doi:10.1101/gr.126516.111pmid:22009989
[8]	Warren RL, Freeman DJ, Pleasance S, et al. Co-occurrence of anaerobic bacteria in colorectal carcinomas[J]. Microbiome, 2013, 1(1): 16. DOI: 10.1186/2049-2618-1-16. doi:10.1186/2049-2618-1-16pmid:24450771
[9]	Weng YJ, Gan HY, Li X, et al. Correlation of diet, microbiota and metabolite networks in inflammatory bowel disease[J]. J Dig Dis, 2019, 20(9): 447-459. DOI: 10.1111/1751-2980.12795. doi:10.1111/1751-2980.12795
[10]	Rubinstein MR, Wang X, Liu W, et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin[J]. Cell Host Microbe, 2013, 14(2): 195-206. DOI: 10.1016/j.chom.2013.07.012. doi:10.1016/j.chom.2013.07.012pmid:23954158
[11]	Brennan CA, Garrett WS. Gut microbiota, inflammation, and colo-rectal cancer[J]. Annu Rev Microbiol, 2016, 70:395-411. DOI: 10.1146/annurev-micro-102215-095513. doi:10.1146/annurev-micro-102215-095513
[12]	Proença MA, Biselli JM, Succi M, et al. Relationship between Fusobacterium nucleatum, inflammatory mediators and microRNAs in colorectal carcinogenesis[J]. World J Gastroenterol, 2018, 24(47): 5351-5365. DOI: 10.3748/wjg.v24.i47.5351. doi:10.3748/wjg.v24.i47.5351
[13]	Jia YP, Wang K, Zhang ZJ, et al. TLR2/TLR4 activation induces Tregs and suppresses intestinal inflammation caused by Fusobacte-rium nucleatum in vivo[J]. PLoS One, 2017, 12(10): e0186179. DOI: 10.1371/journal.pone.0186179. doi:10.1371/journal.pone.0186179
[14]	Wang Q, Zhao L, Xu C, et al. Fusobacterium nucleatum stimulates monocyte adhesion to and transmigration through endothelial cells[J]. Arch Oral Biol, 2019, 100:86-92. DOI: 10.1016/j.archoralbio.2019.02.013. doi:10.1016/j.archoralbio.2019.02.013
[15]	Tang B, Wang K, Jia YP, et al. Fusobacterium nucleatum-induced impairment of autophagic flux enhances the expression of proinflammatory cytokines via ROS in Caco-2 cells[J]. PLoS One, 2016, 11(11): e0165701. DOI: 10.1371/journal.pone.0165701. doi:10.1371/journal.pone.0165701
[16]	Wu J, Li Q, Fu X. Fusobacterium nucleatum contributes to the carcinogenesis of colorectal cancer by inducing inflammation and suppressing host immunity[J]. Transl Oncol, 2019, 12(6): 846-851. DOI: 10.1016/j.tranon.2019.03.003. doi:10.1016/j.tranon.2019.03.003
[17]	Bashir A, Miskeen AY, Hazari YM, et al. Fusobacterium nucleatum, inflammation, and immunity: the fire within human gut[J]. Tumour Biol, 2016, 37(3): 2805-2810. DOI: 10.1007/s13277-015-4724-0. doi:10.1007/s13277-015-4724-0
[18]	Gur C, Ibrahim Y, Isaacson B, et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack[J]. Immunity, 2015, 42(2): 344-355. DOI: 10.1016/j.immuni.2015.01.010. doi:10.1016/j.immuni.2015.01.010
[19]	Ye X, Wang R, Bhattacharya R, et al. Fusobacterium nucleatum subspecies animalis influences proinflammatory cytokine expression and monocyte activation in human colorectal tumors[J]. Cancer Prev Res (Phila), 2017, 10(7): 398-409. DOI: 10.1158/1940-6207.CAPR-16-0178. doi:10.1158/1940-6207.CAPR-16-0178
[20]	Keku TO, McCoy AN, Azcarate-Peril AM. Fusobacterium spp. and colorectal cancer: cause or consequence?[J]. Trends Microbiol, 2013, 21(10): 506-508. DOI: 10.1016/j.tim.2013.08.004. doi:10.1016/j.tim.2013.08.004
[21]	Edin S, Wikberg ML, Dahlin AM, et al. The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer[J]. PLoS One, 2012, 7(10): e47045. DOI: 10.1371/journal.pone.0047045. doi:10.1371/journal.pone.0047045
[22]	Edin S, Wikberg ML, Oldenborg PA, et al. Macrophages: good guys in colorectal cancer[J]. Oncoimmunology, 2013, 2(2): e23038. DOI: 10.4161/onci.23038. doi:10.4161/onci.23038
[23]	Park HE, Kim JH, Cho NY, et al. Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma[J]. Virchows Arch, 2017, 471(3): 329-336. DOI: 10.1007/s00428-017-2171-6. doi:10.1007/s00428-017-2171-6
[24]	Yu T, Guo F, Yu Y, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy[J]. Cell, 2017, 170(3): 548-563.e16. DOI: 10.1016/j.cell.2017.07.008. doi:10.1016/j.cell.2017.07.008
[25]	Zhang S, Yang Y, Weng W, et al. Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer[J]. J Exp Clin Cancer Res, 2019, 38(1): 14. DOI: 10.1186/s13046-018-0985-y. doi:10.1186/s13046-018-0985-y
[26]	Baldin V, Lukas J, Marcote MJ, et al. Cyclin D1 is a nuclear protein required for cell cycle progression in G1[J]. Genes Dev, 1993, 7(5): 812-821. DOI: 10.1101/gad.7.5.812. doi:10.1101/gad.7.5.812
[27]	Chen Y, Peng Y, Yu J, et al. Invasive Fusobacterium nucleatum activates beta-catenin signaling in colorectal cancer via a TLR4/P-PAK1 cascade[J]. Oncotarget, 2017, 8(19): 31802-31814. DOI: 10.18632/oncotarget.15992. doi:10.18632/oncotarget.15992
[28]	Hur K, Toiyama Y, Okugawa Y, et al. Circulating microRNA-203 predicts prognosis and metastasis in human colorectal cancer[J]. Gut, 2017, 66(4): 654-665. DOI: 10.1136/gutjnl-2014-308737. doi:10.1136/gutjnl-2014-308737
[29]	Yang Y, Weng W, Peng J, et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-κB, and up-regulating expression of microRNA-21[J]. Gastroenterology, 2017, 152(4): 851-866.e24. DOI: 10.1053/j.gastro.2016.11.018. doi:10.1053/j.gastro.2016.11.018
[30]	Hong J, Guo F, Lu SY, et al. F. nucleatum targets lncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer[J]. Gut, 2021, 70(11): 2123-2137. DOI: 10.1136/gutjnl-2020-322780. doi:10.1136/gutjnl-2020-322780pmid:33318144
[31]	Bullman S, Pedamallu CS, Sicinska E, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer[J]. Science, 2017, 358(6369): 1443-1448. DOI: 10.1126/science.aal5240. doi:10.1126/science.aal5240pmid:29170280
[32]	Rubinstein MR, Baik JE, Lagana SM, et al. Fusobacterium nucleatum promotes colorectal cancer by inducing Wnt/β-catenin modulator Annexin A1[J]. EMBO Rep, 2019, 20(4): e47638. DOI: 10.15252/embr.201847638. doi:10.15252/embr.201847638